«It essentially
gives us a periodic table,» Ron DePinho, President of MD Anderson Cancer
Center says, which has provided us with both
diagnostic and therapeutic value as well as helped us design clinical trials to accelerate the development of new cancer drugs,».
«Our study is small, retrospective and all of the patients were located at a single medical
center, but it demonstrates that it's possible to use molecular
diagnostics to identify subgroups of patients more likely to respond to a
given treatment,» said co-first author John Paul Shen, MD, senior clinical fellow and postdoctoral fellow.